Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

48.30
-0.7800-1.59%
Volume:209.61K
Turnover:10.17M
Market Cap:9.23B
PE:-11.80
High:49.08
Open:48.78
Low:48.05
Close:49.08
52wk High:51.86
52wk Low:21.72
Shares:191.17M
Float Shares:151.20M
Volume Ratio:0.66
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0935
EPS(LYR):-2.8793
ROE:-1789.67%
ROA:-41.96%
PB:-5.16
PE(LYR):-16.78

Loading ...

BridgeBio Pharma Announces Upcoming Investor Webinar to Discuss Progress of LGMD2I/R9 Program and Phase 3 Trial Expectations

Reuters
·
Jun 26

BridgeBio Pharma Is Maintained at Buy by B of A Securities

Dow Jones
·
Jun 25

BridgeBio price target raised to $54 from $50 at BofA

TIPRANKS
·
Jun 25

BridgeBio Pharma (BBIO) Gets a Buy from TD Cowen

TIPRANKS
·
Jun 24

BridgeBio Pharma Inc. Concluded Annual Stockholders Meeting

Reuters
·
Jun 24

Evercore ISI Remains a Buy on BridgeBio Pharma (BBIO)

TIPRANKS
·
Jun 23

Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target

MT Newswires Live
·
Jun 17

BridgeBio initiated with an Outperform at Wolfe Research

TIPRANKS
·
Jun 17

BridgeBio Pharma Director Hannah Valantine Reports Disposal of Common Shares

Reuters
·
Jun 12

BridgeBio Pharma Currently Up Nine Consecutive Days, on Pace for Record Winning Streak -- Data Talk

Dow Jones
·
Jun 10

BUZZ-BridgeBio Pharma gains after H.C. Wainwright raises PT

Reuters
·
Jun 10

BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 09

BridgeBio Pharma Inc. to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Reuters
·
Jun 02

Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
May 24

BRIEF-Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

Reuters
·
May 20

BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis

MT Newswires Live
·
May 20

KKR Genetic Disorder L.P. Reports Disposal of Common Shares of BridgeBio Pharma Inc

Reuters
·
May 15

J.P. Morgan Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
May 07

Director Andrew Lo Reports Disposal of Common Shares of BridgeBio Pharma Inc

Reuters
·
May 07

Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating

MT Newswires Live
·
May 05